secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001140361-26-000435
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bepirovirsen Phase 3 positive: primary endpoint met, functional cure rates superior to SOC
--------------------------------------------------------------------------------

- Over 1,800 patients enrolled in two Phase 3 studies (B-Well 1 & 2) across 29 countries.
- Bepirovirsen + SOC achieved statistically significant functional cure rates vs. SOC alone on all ranked endpoints.
- Ionis eligible for up to $150M in regulatory/sales milestones plus 10-12% tiered royalties.
- Global regulatory submissions planned from Q1 2026; potential first finite 6-month CHB therapy.
- Drug has Fast Track FDA, Breakthrough Therapy China, and SENKU Japan designations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036126000435/0001140361-26-000435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036126000435/ef20062477_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-000435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer